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Background: aHUS is a rare, severe, genetic, life-threatening disease of chronic 
complement-mediated TMA. ECU, a terminal complement inhibitor, is approved for the 
treatment of aHUS. Here, we report safety and efficacy results of ECU in adult pts from the 
largest prospective study performed in aHUS.  
Methods: This was a single-arm, Phase 2 trial of ECU in adult pts (≥18 yrs) with aHUS and 
platelets <LLN at screening. Prior plasma exchange or infusion (PE/PI) was not required for 
inclusion. The primary endpoint was the proportion of pts with complete TMA response at 26 
wks. 
 Results: 41 pts enrolled and 38 (93%) received 26 wks of treatment. 30 pts (73%) were 
newly diagnosed (median duration to treatment initiation of 2 weeks). Six pts had no PE/PI 





 24/41 pts (59%) were on dialysis at BL, 20 of whom discontinued by wk 26. Mean (95% CI) 
eGFR increase from baseline was 26.1 mL/min/1.73 m2 (19.8; 32.4: P<0.0001). Two pts who 
were not on dialysis at baseline initiated during the treatment period and remained on dialysis 
through 26 wks. QoL significantly improved. ECU was generally safe and well tolerated. Two 
pts had meningococcal infections; one pt continued ECU. No pts died. Conclusions: ECU 
normalized hematologic parameters and significantly improved renal function and QoL. 83% 
of pts on dialysis at baseline were able to discontinue by wk 26. The results of this 
prospective study confirm that ECU inhibits complement-mediated TMA in adult aHUS pts. 
The study is ongoing. 
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